S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
A gold storm is coming… (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
A gold storm is coming… (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
A gold storm is coming… (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
A gold storm is coming… (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
A gold storm is coming… (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
A gold storm is coming… (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
NASDAQ:ARWR

Arrowhead Pharmaceuticals - ARWR Stock Forecast, Price & News

$36.74
-0.27 (-0.73%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$36.23
$37.71
50-Day Range
$28.00
$40.56
52-Week Range
$26.81
$56.25
Volume
611,328 shs
Average Volume
1.02 million shs
Market Capitalization
$3.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.22

Arrowhead Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
61.2% Upside
$59.22 Price Target
Short Interest
Healthy
4.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.55
Upright™ Environmental Score
News Sentiment
0.68mentions of Arrowhead Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$4.05 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.16) to ($2.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

155th out of 1,029 stocks

Pharmaceutical Preparations Industry

67th out of 501 stocks

ARWR stock logo

About Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Stock News Headlines

Arrowhead Pharmaceuticals (ARWR) to Release Earnings on Monday
I Found a Good-Looking Arrowhead in This Biotech ETF
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
ARWR.C - | Stock Price & Latest News | Reuters
ARWR.MW - | Stock Price & Latest News | Reuters
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
ARWR: Sells Olpasiran Royalty Interest for $250 Million…
5 Top Biotech Stocks To Watch In July 2022
See More Headlines
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Company Calendar

Last Earnings
11/28/2022
Today
2/04/2023
Next Earnings (Confirmed)
2/06/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARWR
Employees
329
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$59.22
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+61.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-176,060,000.00
Pretax Margin
-71.01%

Debt

Sales & Book Value

Annual Sales
$243.23 million
Book Value
$3.95 per share

Miscellaneous

Free Float
102,972,000
Market Cap
$3.92 billion
Optionable
Optionable
Beta
1.02

Key Executives

  • Christopher Richard AnzaloneChristopher Richard Anzalone
    President, Chief Executive Officer & Director
  • Patrick C. O'brienPatrick C. O'brien
    COO, Secretary & Chief Compliance Officer
  • Kenneth Allen MyszkowskiKenneth Allen Myszkowski
    Chief Financial Officer
  • Javier San Martin
    Chief Medical Officer
  • Peter Carignan
    Vice President-Clinical Operations













ARWR Stock - Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARWR shares.
View ARWR analyst ratings
or view top-rated stocks.

What is Arrowhead Pharmaceuticals' stock price forecast for 2023?

9 equities research analysts have issued 1-year price objectives for Arrowhead Pharmaceuticals' stock. Their ARWR share price forecasts range from $31.00 to $90.00. On average, they anticipate the company's stock price to reach $59.22 in the next year. This suggests a possible upside of 61.2% from the stock's current price.
View analysts price targets for ARWR
or view top-rated stocks among Wall Street analysts.

How have ARWR shares performed in 2023?

Arrowhead Pharmaceuticals' stock was trading at $40.56 at the beginning of the year. Since then, ARWR shares have decreased by 9.4% and is now trading at $36.74.
View the best growth stocks for 2023 here
.

When is Arrowhead Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 6th 2023.
View our ARWR earnings forecast
.

How can I listen to Arrowhead Pharmaceuticals' earnings call?

Arrowhead Pharmaceuticals will be holding an earnings conference call on Monday, February 6th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) posted its quarterly earnings results on Monday, November, 28th. The biotechnology company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.24. The biotechnology company earned $31.58 million during the quarter, compared to the consensus estimate of $107.60 million. Arrowhead Pharmaceuticals had a negative net margin of 71.01% and a negative trailing twelve-month return on equity of 40.23%.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Western Financial Corp CA (0.77%), New York State Common Retirement Fund (0.33%), Privium Fund Management B.V. (0.21%), Wealth Effects LLC (0.15%), International Assets Investment Management LLC (0.09%) and Kornitzer Capital Management Inc. KS (0.09%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien and William D Waddill.
View institutional ownership trends
.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $36.74.

How much money does Arrowhead Pharmaceuticals make?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $3.92 billion and generates $243.23 million in revenue each year. The biotechnology company earns $-176,060,000.00 in net income (profit) each year or ($1.68) on an earnings per share basis.

How many employees does Arrowhead Pharmaceuticals have?

The company employs 329 workers across the globe.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for the company is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401.

This page (NASDAQ:ARWR) was last updated on 2/4/2023 by MarketBeat.com Staff